Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial

Authors: Zhang, Cong | Blood | April 15, 2022 | PubMed abstract

Explore all publications

Back To Top